Some diseases were long considered incurable, even untreatable. Epidermolysis bullosa (EB) is one of them. But as technology advances, so…
Magdalena Kegel
Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Magdalena Kegel
A group of physicians and researchers in Germany and Italy were quietly making history in 2015, aware they were doing…
A 7-year-old boy with life-threatening epidermolysis bullosa has German and Italian researchers to thank for acquiring a new skin — and…
Amicus Therapeutics’ Phase 3 trial of SD-101 cream to treat wounds in patients with epidermolysis bullosa did not meet…
In a recent update on its drug development program, Fibrocell Science addressed the therapy, FCX-007, it is developing for people…